PTGS2 and cervical cancer: Data from the RTOG 0128 trial, a phase I-II study testing the COX-2 inhibitor celecoxib and CRT in patients with locally advanced cervical cancer, revealed that patients with low COX-2 expression treated with celecoxib plus CRT had a worse OS compared to patients with a high COX-2 expression [132].